Showing results (311-320 of 8,520) with videos related to

Sort By:
Pageof 852
Alimentary Pharmacology & Therapeutics|January 9, 1999
The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsiaP Moayyedi, S Duffett, D Braunholtz, et al.
Alimentary Pharmacology & Therapeutics|January 9, 1999
Antiinflammatory actions of cat's claw: the role of NF-kappaBM Sandoval-Chacón, J H Thompson, X J Zhang, et al.
Alimentary Pharmacology & Therapeutics|January 20, 1999
Clinical economics review: medical management of inflammatory bowel diseaseF M Ward, K Bodger, M J Daly, et al.
Alimentary Pharmacology & Therapeutics|January 20, 1999
Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infectionJ Martínek, A L Blum, M Stolte, et al.
Alimentary Pharmacology & Therapeutics|January 20, 1999
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study GroupC P Dekkers, J A Beker, B Thjodleifsson, et al.
Alimentary Pharmacology & Therapeutics|January 20, 1999
Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized studyR W McCallum, I Soykan, K R Sridhar, et al.
Alimentary Pharmacology & Therapeutics|January 20, 1999
Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in ratsK Takeuchi, T Hirata, H Yamamoto, et al.
Alimentary Pharmacology & Therapeutics|February 22, 2002
Non-surgical treatment of hepatocellular carcinomaA M Alsowmely, H J F Hodgson
Alimentary Pharmacology & Therapeutics|February 22, 2002
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic reviewE V Loftus, P Schoenfeld, W J Sandborn
Alimentary Pharmacology & Therapeutics|February 22, 2002
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitisJ R B Green, J C Mansfield, J A Gibson, et al.
Pageof 852